Advirna Secures Grant to Develop Modified Double-stranded RNAs for RNAi Research | GenomeWeb

NEW YORK (GenomeWeb) – RNAi research firm Advirna this month secured a six-month, $150,000 grant from the National Science Foundation to develop a novel line of tools based on the gene-silencing technology.

According to the company, which currently markets a line of siRNAs that do not require transfection reagents or delivery vehicles for research applications, the use of existing RNAi technologies for the study of genes in mammalian cells continues to be hampered by off-target effects and high costs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.